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Background: The service weight is among several issues and challenges in the implementation of case-mix in
developing countries, including Malaysia. The aim of this study is to develop the Malaysian Diagnosis Related Group
(MY-DRG) case-mix pharmacy service weight in University Kebangsaan Malaysia-Medical Center (UKMMC) by
identifying the actual cost of pharmacy services by MY-DRG groups in the hospital.
Methods: All patients admitted to UKMMC in 2011 were recruited in this study. Combination of Step-down and
Bottom-up costing methodology has been used in this study. The drug and supplies cost; the cost of staff; the
overhead cost; and the equipment cost make up the four components of pharmacy. Direct costing approach has
been employed to calculate Drugs and supplies cost from electronic-prescription system; and the inpatient pharmacy
staff cost, while the overhead cost and the pharmacy equipments cost have been calculated indirectly from MY-DRG
data base. The total pharmacy cost was obtained by summing the four pharmacy components’ cost per each MY-DRG.
The Pharmacy service weight of a MY-DRG was estimated by dividing the average pharmacy cost of the investigated
MY-DRG on the average of a specified MY-DRG (which usually the average pharmacy cost of all MY-DRGs).
Results: Drugs and supplies were the main component (86.0%) of pharmacy cost compared o overhead cost centers
(7.3%), staff cost (6.5%) and pharmacy equipments (0.2%) respectively. Out of 789 inpatient MY-DRGs case-mix groups,
450 (57.0%) groups were utilized by the UKMMC. Pharmacy service weight has been calculated for each of these
450 MY-DRGs groups. MY-DRG case-mix group of Lymphoma & Chronic Leukemia group with severity level three
(C-4-11-III) has the highest pharmacy service weight of 11.8 equivalents to average pharmacy cost of RM 5383.90. While
the MY-DRG case-mix group for Circumcision with severity level one (V-1-15-I) has the lowest pharmacy service weight
of 0.04 equivalents to average pharmacy cost of RM 17.83.
Conclusion: A mixed approach which is based partly on top-down and partly on bottom up costing methodology has
been recruited to develop MY-DRG case-mix pharmacy service weight for 450 groups utilized by the UKMMC in 2011.
Keywords: Diagnosis related groups, Pharmacy, Service weight, MalaysiaBackground
Drug costs constitute the majority of health system phar-
macy budgets and continue to increase faster than other
health care expenditures [1]. It is accounting for more
than 15.2% of total health expenditure in the world in
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unless otherwise stated.average across OECD countries [3]. In 2006, Pharmaceut-
ical spending ranges from a mean of (19.7% to 30.4%) in
the high-income countries and the low-income countries
respectively as a share of total health expenditure [4].
However, one third of the world population lacks reliable
access to essential drugs [2].
Falkenberg and Tomson [5] indicated that “around
50% of all medicines worldwide are prescribed, dis-
pensed, or sold inappropriately”. These inefficient and
ineffective uses of medicines make it continuously a tar-
get for cost control, management evaluation and policy
regulation [1,6].al. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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1960s as a system comparing resource utilization across
groups of patients with the same principal diagnosis
greatly facilitated pharmacoeconomic evaluation [7]. The
major determinant of pharmacy expenditure in any
health institution is the patient complexity, so for a more
effective drug costs control, methods for case mix adjust-
ment should be considered [8].
Today more than 40 countries worldwide implemented
case-mix system for various purposes and in varying
levels [9,10]. The importance of the Case mix and associ-
ated cost weights is directly proportional with the in-
creasing demand for the development of new hospital
funding methodologies in many countries. The integrity
of both the case-mix grouper algorithm employed and
the associated relative cost weights has a direct impact
on the integrity of these new funding methodologies.
While, the calculation of cost weights and the develop-
ment of a case-mix grouper depends on the availability of
patient level case cost [11,12].
Cost is the resources spent to generate the benefits.
Resources may be in the form of money, time, labour or
other resources used to produce a product such as
health services. However, the calculation of actual costs
is not easy issue and commonly it is based on best esti-
mates and averages across the hospital system. It was
noted that during the implementation of case-mix based
payment systems the attention was focused on the cod-
ing and generation of accurate and comprehensive DRG
activity data. This interest is mainly because the method-
ologies analyzing activity patterns are well established
and standards for DRG classification and coding are well
documented, as well as the accurate patient’s records
that have been properly coded into grouper make the
case-mix data quite acceptable for the purpose of defin-
ing hospital production. Thus, the costing of hospital
services including the pharmacy is often neglected unin-
tentionally. The price is different to cost, but without
the understanding of costs, pricing is not possible. If
prices are difficult to set, then payment models that
fairly pay for what hospitals produce cannot be formu-
lated [13,14].
UKMMC is one of the leading hospitals in Malaysia
that implemented the case-mix system in 2002, as an ap-
propriated provider payment mechanism, in line with
continues national health reform process towards the
provision of equitable and efficient health services [15].
“Cost weights or the relative weights are an important
component of prospective payment system, since they
provide the variation in payment levels that reflect the
relative resources required for visits within each classifi-
cation group” [16]. Cost weight was among several issues
and challenges that faced the implementation of case-
mix in Malaysia [17]. This study aimed to develop thepharmacy service weights in UKMMC by identifying the
pharmacy services and the actual cost of care.
Methodology
Study background
This was a retrospective study with data collected from
inpatients pharmacy electronic prescription and the
Case-Mix database of University Kebangsaan Malaysia
Medical Center (UKMMC) of year 2011. UKMMC was
formed as a result of the amalgamation of the Faculty
of Medicine and Hospital of University Kebangsaan
Malaysia (HUKM) in early 2008. The Centre provides a
broad range of teaching and tertiary referral services in
over 1050 licensed inpatient beds, supported by extensive
outpatient services, in addition to the primary emergency
reception centre for the south eastern suburbs of Kuala
Lumpur, the capital city of Malaysia. In 2011, there were
384, 496 outpatient and 35, 303 inpatient occasions of
services reported in this hospital (i.e. number of admis-
sions or number of admitted patients). The total budget
of the UKMMC was in excess of 473 million Malaysian
Ringgit (USD 150 million) with a 3453 total number of
staff and covered area of 90203.00 (m2). Currently the
UKMMC consists of a hospital, Faculty of Medicine,
Institute of Medical Molecular Research (UMBI) and
affiliated with UKM for teaching undergraduate and post
graduate medical students [18,19].
Profile of UKMMC pharmacy
The UKMMC pharmacy is in charge of pharmacy ser-
vices for all in and outpatients of UKMMC. The total
pharmacy budget (drugs and supplies only) of 2011
was in excess of RM 89,870,771 equivalent to USD
28,466,240 (Exchange Rate of 27th August 2014) with a
123 total number of staff and covering area of 2187 (m2).
The UKMMC pharmacy office allocated almost 16% (RM
13, 880, 484.98) of the annual pharmacy drugs and sup-
plies budget to inpatient services and recruiting only 16%
(20 persons) of the total staff to manage and distribute
inpatient services [19].
Sample size and study period
The study used information on the pharmacy costs of all
patients admitted to UKMMC from 1st January to 31st
December 2011, comprising the 35, 303 separations. The
average length of stay (ALOS) of these patients was
5.5 days, representing 193,824 days of patient care [19].
DRG assignment
In this study, over 20,192 inpatient electronic-prescriptions
with ALOS of 6.6 days were assigned a DRG. There were
633 DRGs identified in the study, 10.3% of which had only
1 case and 28.9% had less than 5 cases. DRG O-6-12-I, Va-
ginal Delivery with other Procedure Excluding Sterilization
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ume DRG identified in this study. The range of length of
stay varied from 1 to 69 days, and the highest proportion
of patients (16.4%) and (20.6%) separated on the second
and third day after admission respectively.
Data issues
The following steps have been done to develop the MY-
DRG case-mix pharmacy service weight in UKMMC by
identifying the actual cost of pharmacy services by MY-
DRG groups in the hospital.
Step one: identifying the pharmacy component
In order to estimate the total costs of a particular health
service, it is important to identify all the relevant costs
and those who bear these costs [20]. In this study the
pharmacy component has been identified to include four
main contributors:
 The drugs and supplies cost.
 The cost of in-patient pharmacy staff.
 The overhead cost centres allocation.
 The pharmacy equipment cost.
Step two: calculation of the total pharmacy cost
A mixed approach which is based partly on top-down
(step-down) and partly on bottom up or activity based
(ABC) costing methodology has been recruited in order
to calculate the pharmacy cost per patient or episodes
[15,21]. The required data (retrospective data) for ABC
approach were the all inpatient e-prescriptions and the
total number of the inpatient pharmacy staff for year
2011 in UKMMC. While the data needed for top down
costing were the total of hospital expenditures, total
number of hospital staff, total hospital floor area and
total number of inpatients for year 2011, in UKMMC.




Number of staff Floor area
1 The administrative, The maintenance
2 General store and consumable Utility
3 IT centre Cleaning ServicesThe main purpose of this step is to determine the
pharmacy use of the indirect (overhead) cost
centers. Normally starts (at the top) with total
expenditures and then divides these by a measure
of total output (e.g. patient visits, days or
admissions) to give an “average” cost per patient
per visit, per day or per admission [22,23]. The
top-down approach is cheaper and faster than a
bottom up approach because of less data intensive
and fewer research skills needed and data can be
collected from routine resources [15].4 Library Security
5 Tax and insurance CSSD centers
6 Rent
7 Telephone and fax centersThe pharmacy use of the overhead cost centers and
allocation factors
The overhead cost centers included in this study are the
administration, maintenance, utility, cleaning services,security, general store and consumable, information tech-
nology (IT) centre, library, tax and insurance, rent, The
central sterile services department (CSSD), telephone
and fax centers. Data on the annual total cost for each
center has been collected from the financial department
of UKMMC. Table 1 shows the overhead cost centers
and the appropriate allocation factors used to determine
the pharmacy use of the indirect (overhead) cost centers.
The following questions have been used to calculate the
pharmacy use of each of the overhead cost centers: The
pharmacy use of the indirect (overhead) cost centers =
(Number of pharmacy staff/total hospital staff ) × (annual
total cost) or the pharmacy use of the indirect (overhead)
cost centers = (pharmacy floor area/total hospital floor
area) × (annual total cost). Summing up all the alloca-
tions gave the total pharmacy use of the indirect (over-
head) cost centers. Then the total pharmacy use of the
indirect (overhead) cost centers multiplied by the in-
patient proportion to get the inpatient pharmacy use of
the indirect (overhead) cost centers. The results of this
question divided by total annual number of (inpatient
days) to get the inpatient pharmacy use cost per day. This
unit cost in the question was then multiplied by (the
length of stays) of investigated patient to get the inpatient
pharmacy use cost per patient per day, Figure 1.
The pharmacy equipment cost (capital costs)
In this costing study the pharmacy capital costs com-
prised of all the purchased or donated equipments, furni-
ture and vehicles in the last 5 years (RM 642,375.16). The
information was obtained from the financial department
in the hospital. The total capital cost has been divided by
Annualization factor (4.32) at 5% discount rate [24]. The
result (RM148, 697.95) has been multiplied by inpatient
proportion (16%) which already determined by The
UKMMC pharmacy office. Then the inpatient pharmacy
capital asset costs (RM 23, 791.67) divided by the total
number of inpatient days (193824) to get the capital as-
sets cost per day. This unit cost (0.12) in the question
was multiplied by length of stays of the investigated
Costing Approaches
Step Down Costing 
(Indirect Costing)




Unit Cost (3.62) X LOSUnit Cost (0.12) X LOS
Unit cost (variable)Unit Cost (4.07) X LOS
Total Pharmacy Cost per MY-DRG
Data Trimming
Pharmacy service weight 
Figure 1 Study costing strategy.
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per patient per day.
b. Bottom-up or Activity based costing and data
collection:
The Bottom-up costing requires recording of every
item of service that a patient receives, and changing
them into costs. Bottom-up costing gives more
accurate results, but it requires a large investment in
time and resources [24,25]. In this study the
bottom-up approach was used 1) to estimate drug
and supply cost per episode and 2) to cost inpatient
staff of the pharmacy per patient.Costs of pharmacy staff serviced inpatients
Direct cost for staff cost covered all in-patient pharmacy
staff responsible for supplying medications to all wards
and units in UKMMC. Basic salaries and additional
allowances, bonuses, contributions, payments were ob-
tained from the staff directly and confirmed by hospital
personnel services administrative records. Summing up
all in-patient pharmacy staff costs gave the total staff cost
(RM 702,030.48). Then the total staff cost was divided by
total annual number of inpatient days (193824) to get
staff cost per day. This unit cost (3.62) was then multi-
plied by (length of stay) of investigated patient to esti-
mate staff cost per patient per day.Cost of inpatient drugs/medicines and medical supplies
Information on the drugs/medicines, fluids and medical
supplies prescribed to the patient was obtained from
electronic-prescription system on Excel based file. Elec-
tronic prescribing refers to the ordering, administration
and supply of drugs is completely supported by electronic
systems. Each e-prescription defined as one episode (a
period of inpatient care) [26] having data on registration
number (MRN) which is a unique number given for each
local and international client; name of the patient; e-
prescription number; date of prescription; number of
items, quantity, duration and name of the prescribed
medicines, fluids and supplies. Drugs prescribed and
purchased by patients for take home were excluded.
List of acquisition unit costs (price) of each drug and
supplies were obtained from the UKMMC pharmacy
office. This unit cost was then multiplied by the quan-
tity of the corresponding item to estimate cost per
item. Then we summed up the cost of all items in one
e-prescription to estimate drug cost per patient (per
episode).
Calculation of patient level total pharmacy costs
The total pharmacy cost of each individual patient/epi-
sode would be the summing of total drugs and supplies
cost plus the results of multiplying the unit cost of each
of pharmacy use of overhead cost centers; the pharmacy
Table 2 Unit costs of the four pharmacy components
No. Pharmacy components Unit cost (RM)
1 Total drugs and supplies cost Episode/variable
2 Pharmacy staff cost 3.62
3 Pharmacy use of overhead cost centers 4.07
4 Pharmacy equipment cost 0.12
Table 3 Frequency distribution of the average pharmacy
components cost
No. Pharmacy components Average (RM) %
1 Total drugs and supplies cost 315.15 85.98
2 Pharmacy staff cost 23.81 6.50
3 Pharmacy use of overhead cost centers 26.78 7.31
4 Pharmacy equipment cost 0.79 0.22
Average total pharmacy cost (n = 20,192) 366.53 100
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tigated patient/episode.
Step three: data trimming
The L3H3 method (Lower three Higher three), is data
trimming method commonly used to ensure that the
means reported more accurately represent the central
tendency amongst cases analyzed [27]. For each DRG we
calculated the total and the average pharmacy cost de-
pending on the number of patients/episodes in that
DRG. Trimming method mainly consists of using the
average pharmacy cost for every MY-DRG having more
than 20 patients/episodes divided by three as the low
trim point and the average pharmacy cost multiplied by
three as the high trim point. So, in term of distribution
the normal cases in each MY-DRG lie inside the trim
points and known as inliers. In contrast, the cases which
lie outside the trim points considered skewed or outlier
cases and have been excluded from analysis.
Step four: calculation the pharmacy service weight per
each MY-DRG
Pharmacy service weight was defined as the burden of
work or services performed by pharmacy component and
the resources used for a patient compared to the burden
of other services for others DRGs. The actual service
weights are unit less numbers that express the expected
cost for one visit in relation to average visit. The best way
to calculate service weights is to use actual cost per in-
patient case by assigning each DRG a relative value that
reflects the cost of any one, or all, of the resources con-
sumed (e.g. bed-days, theatre time, drugs, diagnostic pro-
cedures, physiotherapy and nursing treatment) in that
respective DRG when compared with all DRGs [28,29].
In order to estimate the pharmacy service weight we
need first to calculate the average pharmacy cost for all
MY-DRGs. The closest average cost among all the MY-
DRGs would be the base used to calculate the pharmacy
service weight using the following question:
Pharmacy service weight of a MY-DRG = Average
pharmacy cost of the investigated MY-DRG/Average of a
specified MY-DRG (which usually the average pharmacy
cost of all MY-DRGs).
Ethics
This study was approved by ethics committee of National
University of Malaysia- Medical Center (UKMMC), code
number (UNU-002- 2013) in 20 May 2013.
Results
The pharmacy component unit costs
Table 2 shows the estimated unit costs of the pharmacy
components with exception of the drugs and supplies
unit cost which is variable depending on the number ofitems and the quantity of drugs and supplies consumed
by each patient (episode).
The pharmacy component
The total and the average pharmacy cost have been cal-
culated for each MY-DRG using the estimated unit costs.
Table 3 reports the frequency distribution of the average
pharmacy components cost: Drugs and supplies were
the main component (86.0%) of pharmacy cost com-
pared to overhead cost centers (7.31%), staff cost (6.50%)
and pharmacy equipments (0.22%) respectively.
After data trimming
After data trimming and excluding DRGs with less than
5 cases, 13,663 cases with ALOS of 7 days were available
for analysis. There were 450 DRGs identified in the
study, 5.6% of which had only 5 cases. DRG O-6-13-I,
Vaginal Delivery with severity level one (5.0%) was the
highest volume DRG identified in this study. Almost
61.3% of total separations were classified as medical and
39.7% of them were classified into the surgical partition.
Pharmacy service weight
Average pharmacy cost of all MY-DRGs was 484.48.
MY-DRG F-4-16-III, Dementia and Other Organic Brain
Disturbances Including Mental Retardation with severity
level three was the closest average (486.08) among all
other MY-DRGs. Thus this average was the base (de-
nominator) used in the question to estimate the phar-
macy service weight for all MY-DRGs. Table 4 shows the
pharmacy service weight of the highest 20 MY-DRGs.
MY-DRG case-mix group of Lymphoma & Chronic
Leukemia group with severity level three (C-4-11-III)
has the highest pharmacy service weight of 11.8 equiva-
lents to average pharmacy cost of RM 5383.90. While
the MY-DRG case-mix group for Circumcision with
Table 4 Pharmacy service weights of the highest 20
MY-DRGs












1 C-4-11-III 38 204588.16 5383.90 11.8
2 B-1-10-III 11 49817.84 4528.89 9.32
3 J-1-20-III 5 22178.34 4435.67 9.13
4 U-1-20-III 17 61664.92 3627.35 7.46
5 M-1-20-III 5 16848.74 3369.75 6.93
6 C-4-10-III 31 104232.86 3362.35 6.92
7 G-1-11-III 14 46170.40 3297.89 6.78
8 M-1-60-III 8 22978.67 2872.33 5.91
9 S-4-13-III 6 17148.36 2858.06 5.88
10 D-4-10-III 13 34282.24 2637.10 5.43
11 B-1-11-III 7 18080.84 2582.98 5.31
12 M-1-03-III 11 26994.90 2454.08 5.05
13 J-4-12-III 9 20444.37 2271.60 4.67
14 G-4-21-III 5 10925.50 2185.10 4.50
15 D-1-10-I 9 18569.22 2063.25 4.24
16 I-4-13-III 6 11693.31 1948.89 4.01
17 I-1-04-III 5 9550.77 1910.15 3.93
18 D-1-20-III 5 9455.59 1891.12 3.89
19 K-1-20-III 16 30134.09 1883.38 3.87
20 I-4-14-III 10 18375.21 1837.52 3.78
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service weight of 0.04 equivalents to average pharmacy
Cost RM 17.83.
Limitation of study
This study has few areas of limitations. First of all, this
study was not designed to cover a representative size of
hospitals in Malaysia due to time and resource con-
straints in addition to the limited number of hospitals
that implemented DRG system in Malaysia. Other limi-
tation is related to (date) of e-prescription issue which
was not always be the same date of patient admission.
This limitation made the joining of e-prescription data
to MY-DRG data base to be done manually.
Discussion
The main objective of this study was to develop the MY-
DRG inpatient pharmacy service weight in UKMMC
using E-prescription data and DRG data base in UKMMC.
For this purpose a mixed approach of top-down and
bottom-up costing methodology has been recruited
jointly [24].
Although international literature indicated that there
are several approaches to estimate the cost of providing
services by health related institution including hospitals.However, there is no unique, appropriate and acceptable
methodology for costing hospital services [30]. Type of
the service and reason for costing in addition to eco-
nomical feasibility of cost calculation are the main deter-
minants for selection of appropriate costing approach.
Thus, the cost of a particular service can vary substan-
tially according to the purpose of cost data for which it
was generated [31].
This study indicated that the drugs and supplies made
the highest component of the pharmacy cost. These find-
ings come in line with other international and local stud-
ies considering the pharmacy services as ancillary
services [27] and among the highest components of cost
in the hospital [28,29,32]. To our knowledge, the phar-
macy services and its related weights are commonly stud-
ied within the general hospital level costing and are
rarely to be evaluated as an independent subject [27,33].
Costing study done in Philippine for selected hospitals
used both the activity based and top down costing ap-
proaches found that medicines and supplies cost more
than 25% of the total hospital cost [33]. In 2004, two stud-
ies done in UKMMC, and the costing analysis were con-
ducted based on the case-mix concept of the top-down
costing approach. The first one was to study the cost ana-
lysis for cardiology. This study found that the three biggest
components of medical cardiology cases are ICU cost
(38.0%), Pharmacy component (14.2%) and Ward Services
(12.7%). In the Surgical Cardiology, the biggest compo-
nent of cost was the Operation Theatre (27.9%), followed
by ward Services (25.4%) and Pharmacy Component
(8.5%) [15]. The other study was the cost analysis and cost
weight for the treatment of orthopedic cases in HUKM.
This study showed that the top three components of cost
for the treatment of medical orthopedic was Pharmacy
Services (22.3%), followed by Ward Services which was
(20.7%) and Laboratory Services which was (12.1%), while
the top three components of cost for treatment of surgical
orthopedic was Operating Theatre Services which was
(21.2%), followed by Pharmacy Services which was (17.6%)
and Ward Services which was (16.3). It is noted that for
both the medical and surgical partitions of cardiology and
orthopedic cases, the pharmacy component services were
among the top three contributors of the large portion of
cost or resources [34].
Indeed, the actual drug costs and the pharmacy cost
are being among the main objectives of much research
in the health care economy [29,35]. Although there is
considerable variation between countries, the develop-
ing countries (the upper middle-income, the lower
middle-income and the low-income countries) contrib-
ute only to 21.5% of the total global pharmaceutical ex-
penditures in 2006; however they spend proportionally
more of their health budget on medicines than the de-
veloped countries [4,36].
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would greatly facilitate the activity based costing method-
ology to estimate the pharmacy service weight by identi-
fying pharmacy services and the actual cost of care. In
fact, the availability of pharmacy service weights or cost
weights will enable a comparison is made between the
treatments cost of various DRG cases within and be-
tween hospitals [17]. For the purpose of using DRG as a
base of hospital payment, a price needs to be assigned to
each DRG. This is usually done by assigning a cost rela-
tivity (or service weight) with a base price multiplier [13].
Conclusion
A mixed approach which is based partly on top-down
and partly on bottom up costing methodology has been
recruited to develop MY-DRG case-mix inpatient phar-
macy service weight for 450 groups utilized by the
UKMMC in 2011. This methodology can be used for cal-
culating pharmacy service weight among Government
Hospital such as General, District and private hospital in
future. It is a hope that the results of this study will
participate in the development of MY-DRG in UKMMC
specifically in pharmacy services by identifying which
DRG consumes the bulk of the resources. So, this can
greatly support decision maker regarding budget planning
of pharmacy services and patients’ outcomes, and eventu-
ally will contribute in the quality of care and services im-
provement as well as an effective use of resources.
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